We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Algorithm Detects and Identifies Novel Bacterial Organisms

By LabMedica International staff writers
Posted on 19 Jan 2024
Print article
Image: The reliable identification of cultivated germs is essential in clinical bacteriology (Photo courtesy of University Hospital Basel)
Image: The reliable identification of cultivated germs is essential in clinical bacteriology (Photo courtesy of University Hospital Basel)

Hospitals frequently encounter unknown germs, and identifying these pathogens is crucial for efficient bacterial infection treatment. Typically, medical laboratory analysis can identify these pathogens, but standard methods sometimes fall short, especially when dealing with unclassified bacterial species or those difficult to cultivate. Since 2014, a dedicated research team has been collecting and analyzing patient samples containing such elusive germs, leading to the discovery of over 30 new bacteria species, some linked to significant clinical infections.

The team at the University of Basel (Basel, Switzerland) examined a total of 61 unidentified bacterial pathogens from various patient blood and tissue samples. These pathogens had previously eluded identification by conventional lab techniques like mass spectroscopy or partial bacterial genome sequencing. The researchers then employed a more recent method to sequence the complete genetic material of these bacteria. By comparing the genomes with known strains using an online tool, they identified 35 previously unknown bacteria out of the 61 samples. The remaining 26 strains were classified as difficult to identify. These strains either had their genome sequences recently added to databases or had only recently received accurate taxonomic descriptions. Upon reviewing patient data, they found that seven of the 35 new strains had clinical relevance, indicating their potential to cause bacterial infections in humans. Most of these newly identified species belong to the Corynebacterium and Schaalia genera, gram-positive bacilli typically part of the natural human skin microbiome and mucosa. Although often overlooked and understudied, these species can lead to infections when they enter the bloodstream, such as through a tumor.

One particularly challenging pathogen and potentially clinically significant was identified in a patient's inflamed thumb following a dog bite. This finding led the Basel team to consider it an emerging pathogen requiring close monitoring. Similarly, a Canadian research group isolated this bacterium from wounds inflicted by dog or cat bites, naming it Vandammella animalimorsus in 2022. The Basel team is also planning to name their new species, with two already named: Pseudoclavibacter triregionum, referring to Basel's location near Switzerland, France, and Germany's borders. The project is ongoing, with the team at the University Hospital Basel continuing to collect and sequence unknown pathogens from patient samples. They have already identified over 20 additional new species. This ongoing research is crucial for the future of medical diagnostics, as it will enable more accurate diagnoses and effective treatment of infections caused by rare pathogens right from the start.

“Such direct links between newly identified species of bacteria and their clinical relevance have rarely been published in the past,” said microbiologist Dr. Daniel Goldenberger who led the team. “We have noticed a major dynamic here: thanks to technological advances in bacteriology, much more is being published about newly discovered species of bacteria.”

Related Links:
University of Basel

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.